Skip to main content
Premium Trial:

Request an Annual Quote

Techne Acquires Reagents Maker Tocris

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Techne today announced that it has acquired life science research reagents maker Tocris Holdings and its subsidiaries for £75 million ($124 million) in cash.

Bristol, UK-based Tocris makes reagents that are used in a wide variety of research areas, such as angiogenesis, cell metabolism, signal transduction, stem cells, as well as in pharmacological studies of ion channels, nuclear receptors, transporter molecules, and enzymes. Its offerings will be combined with those of Techne's R&D Systems subsidiary, which provides purified cytokines, antibodies, and assay kits that are sold to biomedical researchers and clinical research labs.

Tocris had 2010 revenues of £11.7 million and EBITDA of £7.4 million. Techne expects the acquisition to add around $3.5 million to its fourth-quarter 2011 sales and said that it is expected to be slightly dilutive to its fourth-quarter 2011 and fiscal-year 2012 net earnings.

Tocris will continue its product development, marketing, and sales activities from Bristol and will coordinate with R&D Systems and its re3lated European and Chinese entities to expand product distribution worldwide.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.